Haemonetics Reports Q1 FY2027: Revenue $339.4M, Adjusted EPS $1.14, Raises FY27 Guidance
Haemonetics announced its first-quarter fiscal 2027 results, reporting net revenue of $339.4 million, a 5.6% year-over-year increase, and adjusted earnings per diluted share of $1.14. The company raised its full-year fiscal 2027 revenue and organic growth targets, attributing the strong performance to plasma share …